SLU-PP-332

ERR agonist (small molecule) · C-tier (Dr. Alex Tatem) · Preclinical evidence

A molecule that switches on the same muscle genes aerobic exercise does. Mice ran farther and resisted weight gain; nobody has tested it in people.

Dr. Tatem’s take

C tier — a “true exercise mimetic” that could become huge, but with no human data its role isn’t defined. He hopes you still fit in some cardio.

In Dr. Tatem’s tier list

• Another small molecule, not a peptide. It activates the estrogen-related receptors (alpha, beta, gamma) — metabolism receptors that have nothing to do with estrogen or gynecomastia.
• Activating them turns on pathways normally triggered by cardio, making it a true exercise mimetic, similar in spirit to azelaprag.
• More a biohacking interest than a performance drug; interesting animal data, none in humans.
• Verdict: C tier — a statement on how little information exists, not on the compound.

History & background

SLU-PP-332 was developed in Thomas Burris’s laboratory (originally at Saint Louis University — hence “SLU”) as an activator of estrogen-related receptors. Papers in 2023 showed improved endurance in normal mice and weight loss in obese mice.

It has not entered human trials.

Benefits

• Mice ran about 70% longer and 45% farther.
• Obese mice lost about 12% of body weight in a month without eating less.

Risks

• Unknown in humans.
• Oral absorption in people unknown (mouse studies used injections).

Dosing protocols (informational, labeled by evidence)

• Community (bro science): Community use — Not reliably documented outside seller pages, Oral (or injected), —, —

Status: Unapproved, investigational; no human trials.

Grade and commentary: Dr. Alex Tatem. Watch: Truth About Popular Peptides Tier List (What Works, What’s Overhyped) | Pt. 3. Subscribe: @DrAlexTatem.